Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Front Sports Act Living ; 6: 1416080, 2024.
Article in English | MEDLINE | ID: mdl-38873229

ABSTRACT

Introduction: Master athletes are examples of successful aging. It is not clear whether it is the competitive-oriented training or just the amount of total regular exercise that reduces the age-related decline in physiological functions. We aimed to compare health-related parameters in competitive (C) and physically active older adults (A) that performed the same weekly physical activity (PA) amount. Methods: Seventeen C and 17 A were matched for age (8 and 9 male participants under and over 70 years old respectively, for both groups) and weekly PA amount (GPAQ). Body composition, leg and arm maximal strength, balance and reaction time were measured; moreover, leg and arm exercise efficiency, estimated VO2max, and VO2/HR relationships were evaluated. Perception of life and sleep quality was also assessed through specific questionnaires (SF-36 and PSQI). The effect of group (C vs. A), age (U70 vs. O70) and their interaction was examined through a Two-Way ANOVA test. Results: C dedicated more time to vigorous PA compared to A (p = 0.03), while less to moderate daily work (p < 0.01) and active commuting (p = 0.06). C exhibited better body composition (all p < 0.05), higher leg maximal strength (p < 0.05) and a trend for elevated arm strength (p = 0.06). Reaction time, leg and arm cycling efficiency were similar in the two groups (all p > 0.05), while balance reduced in A O70. Estimated VO2max was higher for C in leg cycling (p = 0.05) and remained constant across ages (all p > 0.05). VO2/HR relationship, life and sleep quality did not differ for groups and ages. Conclusions: Regular physical exercise of about 6,000 METs/week seems to have a beneficial effect on health-related parameters, both in non-structured and competitive PA, when compared to sedentary behaviour. However, the older adults engaged in competitive training exhibit further advantages: better body composition, higher arm and leg muscle strength, and higher leg VO2max. This study highlights the importance of encouraging active lifestyles for maintaining long-term health, high levels of life quality perception and reducing age-related decline. However, vigorous training suitability needs to be verified by a team of PA specialists.

2.
Mult Scler ; 15(2): 212-8, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18805837

ABSTRACT

BACKGROUND: Neutralising antibodies (NAb) to interferon beta (IFN beta) are associated with a reduced bioactivity and efficacy of IFN beta in multiple sclerosis (MS). Unclear is how to apply IFN beta bioactivity measurements (quantification of Myxovirus resistance protein A (MxA) mRNA) in clinical practice. OBJECTIVES: To evaluate value and feasibility of IFN beta bioactivity measurement with a single MxA mRNA measurement for screening and a second measurement before and after IFN beta administration for definite confirmation of IFN beta bioactivity status. METHODS: In 79 MS patients MxA mRNA expression was determined 4 hours after IFN beta administration. If inadequate, MxA mRNA expression testing was repeated 3 months afterwards, comparing post- and pre injection samples to determine whether IFNb bioactivity was persistently lacking. MxA mRNA expression was compared to NA beta titres, determined by the cytopathic effect assay (CPE). RESULTS: NAb titres correlated significantly with MxA mRNA expression and MxA mRNA induction. Of all screened patients, only one patient had adequate MxA mRNA expression and high NAb titres simultaneously. Of the biological non-responders at second measurement (21/55), 17 (81%) were high-titre NAb positive, 1 (5%) was low-titre NAb positive and 3 (14%) were NAb negative. Without considering the pre-injection measurement, two more NAb negative patients would have tested negative for IFN beta bioactivity, emphasizing the need of a pre-injection sample. CONCLUSIONS: Our data suggest that for IFN beta bioactivity screening a single post-injection measurement seems reasonable. However, MxA induction measurement based on both pre- and post-IFN beta injection samples at second measurement is somewhat more precise in determining ultimate IFN beta bioactivity status.


Subject(s)
Drug Monitoring/methods , Immunologic Factors/administration & dosage , Immunologic Factors/immunology , Interferon-beta/administration & dosage , Interferon-beta/immunology , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Adult , Antibodies/immunology , Antibodies/pharmacology , Feasibility Studies , Female , GTP-Binding Proteins/genetics , GTP-Binding Proteins/immunology , Gene Expression Regulation, Viral/drug effects , Gene Expression Regulation, Viral/immunology , Humans , Immunoassay/methods , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/immunology , Myxovirus Resistance Proteins , Neutralization Tests , RNA, Messenger/metabolism , Young Adult
3.
Neurology ; 71(24): 1940-7, 2008 Dec 09.
Article in English | MEDLINE | ID: mdl-18971450

ABSTRACT

BACKGROUND: The cytokine interferon beta (IFNbeta) is successfully used in the treatment of multiple sclerosis (MS), although there is a high degree of variability in the response. A common mechanism involved in the modulation of responsiveness to cytokines is represented by regulation of their receptor expression through autocrine ligand-mediated loops. The present study is aimed at investigating the regulation of IFNalpha/beta receptor (IFNAR) during IFNbeta therapy in patients with MS and at correlating it with the biologic responsiveness to the cytokine. METHODS: Quantitative PCR measurements of IFNAR-1 and the three IFNAR-2 isoforms were performed in 141 patients after short-term and long-term treatment. Patients were also regularly screened for anti-IFNbeta neutralizing antibodies (NAbs). IFN-inducible myxovirus resistance protein A messenger RNA was used as an indicator of bioactivity. RESULTS: Pretreatment levels of IFNAR-2 in patients were lower overall than in controls (p = 0.038), and high levels correlated with greater bioactivity. Upon prolonged treatment, NAb-negative patients displayed a state of decreased transmembrane IFNAR-2 expression (p < or = 0.025), whereas levels of soluble IFNAR-2 were slightly increased (p < 0.0001). The presence of NAbs reversed these effects (p < or = 0.0056). In NAb-positive patients, pretreatment expression levels of both transmembrane IFNAR-2 isoforms were significantly lower than in NAb-negative patients (p < or = 0.0089). CONCLUSIONS: Findings show that interferon-alpha/beta receptor (IFNAR)-2 isoforms are important regulators of the responsiveness to endogenous and systemically administered interferon beta (IFNbeta). They show a dual action, agonistic and antagonistic, that influences both the magnitude and the nature of the biologic response to IFNbeta. Levels of IFNAR-2 are regulated with the aim of keeping the body in a state of equilibrium, even when nonphysiologic stimuli are present.


Subject(s)
Drug Resistance/genetics , Interferon-beta/pharmacology , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Receptor, Interferon alpha-beta/drug effects , Receptor, Interferon alpha-beta/genetics , Alternative Splicing/drug effects , Alternative Splicing/genetics , Alternative Splicing/immunology , Cell Membrane/chemistry , Cell Membrane/genetics , Cell Membrane/immunology , Down-Regulation/drug effects , Down-Regulation/genetics , Down-Regulation/immunology , Drug Resistance/immunology , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Gene Expression Regulation/immunology , Homeostasis/drug effects , Homeostasis/genetics , Homeostasis/immunology , Humans , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Male , Multiple Sclerosis/physiopathology , Polymerase Chain Reaction , Protein Isoforms/drug effects , Protein Isoforms/genetics , Protein Isoforms/immunology , Protein Structure, Tertiary/drug effects , Protein Structure, Tertiary/genetics , RNA, Messenger/analysis , RNA, Messenger/metabolism , Receptor, Interferon alpha-beta/immunology , Retrospective Studies , Up-Regulation/drug effects , Up-Regulation/genetics , Up-Regulation/immunology
4.
Neurology ; 70(13 Pt 2): 1119-27, 2008 Mar 25.
Article in English | MEDLINE | ID: mdl-18272865

ABSTRACT

BACKGROUND: Prolonged therapy with interferon beta (IFN beta) often leads to the development of anti-IFN beta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and is associated with reduced clinical efficacy of therapy. Myxovirus-resistance-protein A (MxA) has proven to be a reliable biomarker of IFN beta bioactivity. We analyzed the prognostic value of MxA mRNA, NAbs, and BAbs on the risk of having a new relapse in IFN beta-treated patients. METHODS: A 3-year study was conducted in 137 IFN beta-treated patients. Blood samples for BAbs, NAbs, and MxA mRNA measurements were taken after 12 +/- 3 months of therapy. Analysis of relapse-free survival (RFS) was performed for all measures by using known thresholds, generating "positive" and "negative" groups. Also, time between sampling and following relapse and risk of new relapses were calculated. RESULTS: The MxA-negative group showed poorer RFS rates than the MxA-positive group [p < 0.0001, hazard ratio (HR) = 2.87]. Likewise, the NAb-positive group showed poorer RFS rates than the NAb-negative group (p =0.0013; HR = 2.49). On the contrary, BAb measurement did not show a clear clinical significance. CONCLUSIONS: Findings indicate that measurements of both myxovirus-resistance-protein A (MxA) and neutralizing antibodies (NAbs) predict the risk of new relapses; however, the slightly stronger prognostic significance of MxA mRNA and the easier method for it measurement make MxA mRNA the preferred biomarker for monitoring interferon beta (IFN beta)-treated patients. This information can be used to better tailor treatment to the individual patient with MS.


Subject(s)
GTP-Binding Proteins/genetics , Interferon-beta/pharmacology , Multiple Sclerosis/diagnosis , Multiple Sclerosis/drug therapy , RNA, Messenger/blood , Adolescent , Adult , Antibodies/analysis , Antibodies/blood , Antibodies/immunology , Biomarkers/analysis , Biomarkers/blood , Disease-Free Survival , Drug Resistance/immunology , Female , Humans , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Leukocytes, Mononuclear/metabolism , Male , Middle Aged , Multiple Sclerosis/blood , Myxovirus Resistance Proteins , Predictive Value of Tests , Prognosis , RNA, Messenger/analysis , Recurrence , Retrospective Studies , Risk Factors , Treatment Outcome
5.
Neurol Sci ; 28(4): 209-11, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17690854

ABSTRACT

We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Immunologic Factors/therapeutic use , Neuromyelitis Optica/drug therapy , Neuromyelitis Optica/physiopathology , Adult , Antibodies, Monoclonal, Murine-Derived , Brain/pathology , Female , Humans , Magnetic Resonance Imaging/methods , Neuromyelitis Optica/pathology , Rituximab , Spinal Cord/pathology
6.
J Immunol Methods ; 321(1-2): 19-31, 2007 Apr 10.
Article in English | MEDLINE | ID: mdl-17335844

ABSTRACT

There are two commonly employed types of bioassays for the detection of neutralizing antibodies (NAbs) against interferon-beta (IFNbeta): the cytopatic effect assay (CPE), and the MxA (myxovirus resistance protein A) protein assay (MPA). This article describes a bioassay based on the real time PCR measurement of mRNA that results from the induction, in cultured human cells, of the MxA gene by IFNbeta. Serum samples from 104 patients with multiple sclerosis (MS) treated with IFNbeta were tested for NAbs using our real time PCR bioassay. NAbs also were measured in the same specimens by the MPA assay and CPE assay. The calibration range of the real time PCR bioassay is 0.125-30 LU/mL. The range of the intra- and inter-assay variations (coefficients of variation in log(10)) were 4.05% (range 0.88%-7.90%) and 4.42% (range 0.31%-9.15%), respectively. Samples of the three commercial preparations of IFNbeta-1a and -1b were measured showing dose-response curves parallel to that of the NIH reference IFNbeta (mean SD at the midpoint of the dose-response curve=5%). In addition, the assay was robust with respect to number of cells plated (i.e., increasing cell densities from 12x10(3)/well to 384x10(3)/well resulted in 3.03% variability in MxA expression normalized with glyceraldehyde-3 phosphate dehydrogenase). NAbs titers measured were closely comparable to those obtained by the MPA [r(spearman)=0.899; 89% of observed agreements; K=0.779] and the CPE [r(spearman)=0.7899); 86%; K=0.729] assays. Despite the obvious disadvantage of cost, when carried out according to quality assurance guidelines for molecular diagnostics the new MxA gene-expression assay (MGA) has significant advantages over the other methods for testing NAbs: it has excellent reliability and reproducibility, and utilizes equipment and methodologies already accessible in many clinical laboratories.


Subject(s)
Antibodies/blood , Biological Assay/methods , Immunologic Factors/immunology , Interferon-beta/immunology , Multiple Sclerosis/immunology , Reverse Transcriptase Polymerase Chain Reaction/methods , Antibodies/immunology , Biological Assay/standards , Calibration , Cell Line, Tumor , Cytopathogenic Effect, Viral/drug effects , Dose-Response Relationship, Drug , Dose-Response Relationship, Immunologic , Encephalomyocarditis virus/drug effects , Encephalomyocarditis virus/pathogenicity , GTP-Binding Proteins/biosynthesis , GTP-Binding Proteins/genetics , Humans , Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Interferon beta-1a , Interferon beta-1b , Interferon-beta/pharmacology , Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Myxovirus Resistance Proteins , Neutralization Tests/methods , RNA, Messenger/biosynthesis , Reference Standards , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction/standards , Sensitivity and Specificity , Time Factors , Up-Regulation/drug effects
7.
Mult Scler ; 12(1): 47-57, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16459719

ABSTRACT

Biological activity of interferon-beta (IFNbeta) can be assessed by measuring IFN-stimulated genes (ISGs). Among them, myxovirus resistance protein A (MxA) appears to have the highest specificity, but it has no role in the pathogenesis of multiple sclerosis (MS). To investigate the reliability of MxA as a biomarker, we compared its expression to that of two other ISGs: TNF-related apoptosis-inducing ligand (TRAIL) and X-linked inhibitor of apoptosis factor-1 (XAF-1). Both were shown to be involved in immunoregulatory mechanisms and might play a role in MS. Quantitative-PCR measurements were performed in peripheral blood mononuclear cells from 73 MS patients after short-term and long-term treatment with IFNbeta. A time-dependent response for multiple ISGs was observed in all patients after short-term treatment. In contrast, long-term treatment induced concurrent inhibition of ISGs in 12.3% (9/73) of patients, in whom neutralizing antibodies (NAbs) were detectable. Besides, 22% (16/73) of chronically treated patients showed a non-NAbs-related abrogation of TRAIL expression. In summary, 1) MxA expression was significantly higher than both TRAIL and XAF-1, and 2) MxA was the most sensitive gene to detect decreased bioavailability due to NAbs. These findings identify MxA as an appropriate biomarker for IFNbeta, although there is no evidence for a functional role of it in MS.


Subject(s)
Apoptosis Regulatory Proteins/genetics , GTP-Binding Proteins/genetics , Interferon-beta/therapeutic use , Membrane Glycoproteins/genetics , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/immunology , Neoplasm Proteins/genetics , Tumor Necrosis Factor-alpha/genetics , Adaptor Proteins, Signal Transducing , Adult , Apoptosis Regulatory Proteins/blood , Biomarkers/blood , Female , GTP-Binding Proteins/blood , Gene Expression Regulation/immunology , Humans , Interferon beta-1b , Intracellular Signaling Peptides and Proteins , Male , Membrane Glycoproteins/blood , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/genetics , Myxovirus Resistance Proteins , Neoplasm Proteins/blood , RNA, Messenger/genetics , Reference Values , TNF-Related Apoptosis-Inducing Ligand , Time Factors
8.
Mult Scler ; 12(6): 738-46, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17263001

ABSTRACT

To date, inter- and intra-laboratory consistency of binding assays for measuring anti-interferon (IFN)beta antibodies has not been assessed. In this investigation, two independent laboratories tested a library of 80 serum specimens obtained from multiple sclerosis (MS) patients treated with IFNbeta. For binding antibodies (BAbs) evaluations, each laboratory used both a capture-ELISA (cELISA) and an enzyme-immuno-assay (EIA), which is commercially available. Samples were also tested for neutralizing antibodies (NAbs). Data demonstrated good intra-laboratory reliability (r(pearson) > or = 0.86), and a good overall agreement between the results obtained from the two centers, using both the cELISA (69/80 of observed agreements) and the EIA (67/80). Accordingly, kappa coefficients (K) showed good concurrence (K > or = 0.651). There was also substantial agreement between cELISA and EIA measurements, as performed in both centers (Orbassano, 66/80, K = 0.631; Basel, 70/80, K = 0.717). However, by comparing NAbs and BAbs titers obtained with both assays, we found that a high degree of BAb-negative samples were positive in NAb-assay. Thus, our study does not support the usefulness of ELISA-based BAb assays as a screening tool for NAbs. Otherwise, BAb-assays can be used as a confirmation test, indicating that the decrease of the biological effects is due to antibodies. In this context, both ELISA-based assays are equally reliable techniques.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Enzyme-Linked Immunosorbent Assay/methods , Interferon-beta/immunology , Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Antibodies/blood , Cell Line, Tumor , Encephalomyocarditis virus/immunology , Enzyme-Linked Immunosorbent Assay/standards , Humans , Immunoassay/methods , Immunoassay/standards , Interferon beta-1a , Interferon beta-1b , Lung Neoplasms , Mass Screening/methods , Mass Screening/standards , Neutralization Tests , Reproducibility of Results
9.
Neurol Sci ; 26 Suppl 4: S213-4, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16388361

ABSTRACT

Relapsing-remitting multiple sclerosis (MS) has a very fluctuating course and responsiveness to interferon beta (IFN-beta) treatment in each patient is extremely difficult. Agreement exists about the negative role of neutralising antibodies (NAbs) on clinical efficacy and markers of IFN-beta bioavailability have been studied; no guidelines exist yet about what to do when a patient becomes NAbs positive or IFN biological activity is lost. In this study 405 MS patients have been longitudinally studied for NAbs and MxA expression. A spontaneous disappearance of NAbs was observed in a few patients with low antibody titre; according to the clinical course, a therapeutic modification has been made in patients persistently NAbs positive; in these patients NAbs persisted over time despite the interruption of IFN therapy.


Subject(s)
Antibodies/blood , GTP-Binding Proteins/blood , Interferon-beta/immunology , Multiple Sclerosis, Relapsing-Remitting/diagnosis , Multiple Sclerosis, Relapsing-Remitting/immunology , Adjuvants, Immunologic/pharmacokinetics , Adjuvants, Immunologic/therapeutic use , Antibodies/genetics , Antibody Formation , Antibody Specificity , Biological Availability , GTP-Binding Proteins/genetics , Humans , Interferon-beta/pharmacokinetics , Interferon-beta/therapeutic use , Longitudinal Studies , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Myxovirus Resistance Proteins , Prognosis , RNA, Messenger/analysis , Treatment Outcome
10.
J Neuroimmunol ; 158(1-2): 195-203, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15589054

ABSTRACT

This study is the first to evaluate biological response to first injections of interferon-beta (IFNbeta) in patients with multiple sclerosis. MxA mRNA was measured in 96 patients receiving IFNbeta-1a (Avonex, n=32), IFNbeta-1b (Betaferon, n=19), IFNbeta-1a (Rebif) 22 microg (n=30), or IFNbeta-1a 44 microg (n=15). Patients were analysed before, 3 and 24 h after the first injection, and 12 h after the second administration. Results showed that up-regulation was evident within 3 h of IFNbeta injection, peaked 12 h after injection, and progressively declined 24 h after administration. The cumulative responses were similar after a single administration, regardless of product/dose. Moreover, data indicate that the abolition of the biological activity detected during IFNbeta therapy is due to underlying phenomena (e.g., neutralizing antibodies), because all patients were constitutively responders to IFNbeta at treatment initiation.


Subject(s)
GTP-Binding Proteins/metabolism , Immunologic Factors/administration & dosage , Interferon-beta/administration & dosage , Multiple Sclerosis/metabolism , Adult , Area Under Curve , Demography , Disability Evaluation , Dose-Response Relationship, Drug , Female , GTP-Binding Proteins/drug effects , GTP-Binding Proteins/genetics , Humans , Immunologic Factors/therapeutic use , Interferon beta-1a , Interferon beta-1b , Interferon-beta/immunology , Interferon-beta/therapeutic use , Male , Middle Aged , Multiple Sclerosis/drug therapy , Myxovirus Resistance Proteins , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Time Factors
11.
J Neurol Neurosurg Psychiatry ; 75(9): 1294-9, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15314118

ABSTRACT

BACKGROUND: MxA gene expression is one of the most appropriate markers of biological activity of exogenous interferon (IFN) beta. METHODS: We quantified MxA mRNA for five consecutive days in 62 patients treated with IFN beta (16, Avonex; 10, Betaferon; 24, Rebif 22; 12, Rebif 44), by quantitative-competitive polymerase chain reaction. Every three months, IFN beta induced neutralising antibodies (NAbs) were evaluated in sera using a cytopathic effect assay. RESULTS: Two categories of patients were identified: one group (49/62) had a sharp post-injection increase in MxA expression (defined as "IFN beta biological responder"), whereas the other group (13/62) had no MxA induction after IFN beta administrations (defined as "IFN beta biological non-responder"). In 11/13 biological non-responders, the persistent presence of NAbs correlated with abolished biological activity, independently of treatment regimen. The two remaining IFN beta biological non-responders were NAb-. Among the 49 IFN beta biological responders, biological activity was comparable between the four preparations on day 2 and 3 (+12 and +36 hours post-injection), but it was greater in Betaferon and both Rebif preparations on day 1, 4, and 5. In biological responders treated three times a week, only 82% (59/72) of injections were considered effective, compared with 100% (13/13) of Avonex injections. CONCLUSION: Our results suggest that an optimal IFN beta regimen is not yet available: Avonex, given once a week, shows lower cumulative biological activity. On the other hand, both Betaferon and Rebif, given three times a week, show 18% biologically ineffective injections and higher risk of developing NAbs, which abolish biological activity.


Subject(s)
Immunologic Factors/pharmacology , Immunologic Factors/therapeutic use , Interferon-beta/pharmacology , Interferon-beta/therapeutic use , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Antibody Formation , Drug Administration Schedule , Female , Humans , Immunologic Factors/administration & dosage , Injections, Subcutaneous , Interferon-beta/administration & dosage , Male , RNA, Messenger/analysis , Retrospective Studies
12.
Neurology ; 62(11): 2031-7, 2004 Jun 08.
Article in English | MEDLINE | ID: mdl-15184610

ABSTRACT

OBJECTIVE: To analyze the impact of neutralizing antibodies (NAbs) on the clinical efficacy of IFNbeta. METHODS: This was an open-label study involving 78 patients with multiple sclerosis treated with Betaferon 8 million IU (MIU) subcutaneously (SC) every other day (n = 20), Rebif 22 micro g SC 3 times weekly (n = 25), or Avonex 30 micro g IM once weekly (n = 33). Every 3 months, blood samples were collected and sera were analyzed for NAbs using an antiviral cytopathic effect assay. Patients were categorized according to their NAb status: NAb negative (NAb-); isolated NAb positive (NAb+), patients with > or =1 positive sample (titer > or = 20); and persistent NAb+, patients with > or =2 consecutive positive samples (titer > or = 20). Patients who were NAb- and persistent NAb+ were compared for relapse rate, time between first and second relapse, percentage of relapse-free patients, and percentage of patients who had a sustained progression of > or =1 point on the Expanded Disability Status Scale (EDSS). RESULTS: The incidence of persistent NAb+ patients was 35% for Betaferon, 20% for Rebif, and 3% for Avonex. During IFNbeta treatment, both NAb+ and NAb- patients showed a reduction in relapse rate; this reduction (25%) was not significant in NAb+ patients but was significant (67%; p < 0.0001) in NAb- patients. In addition, the mean relapse rate was higher (p = 0.039), mean time between first and second relapse was shorter (13 vs 21 months; p = 0.0064), and there was a trend suggesting that NAbs affected the probability of remaining relapse free (p = 0.08). A higher percentage of NAb+ patients versus NAb- patients had worsening of EDSS scores during follow-up (p = 0.013). CONCLUSION: Persistent NAbs significantly reduce the clinical efficacy of IFNbeta.


Subject(s)
Interferon-beta/immunology , Isoantibodies/immunology , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Adolescent , Adult , Aged , Antibody Specificity , Antiviral Agents/immunology , Antiviral Agents/pharmacology , Cell Line, Tumor , Cytopathogenic Effect, Viral/drug effects , Disease Progression , Disease-Free Survival , Drug Resistance , Encephalomyocarditis virus/drug effects , Encephalomyocarditis virus/physiology , Female , Follow-Up Studies , Humans , Incidence , Interferon beta-1a , Interferon beta-1b , Interferon-beta/antagonists & inhibitors , Interferon-beta/pharmacology , Interferon-beta/therapeutic use , Life Tables , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/immunology , Neutralization Tests , Prospective Studies , Severity of Illness Index , Treatment Outcome
13.
Neurol Sci ; 24(3): 130-3, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14600824

ABSTRACT

Devic's neuromyelitis optica (NMO) is a clinical entity characterised by severe transverse myelitis, optic neuropathy and monophasic or recurrent course. We report the case of a woman affected by myelitis and optic neuritis suggesting Devic's disease. Diagnosis was supported by clinical, neuroradiological and biochemical findings. In 14 months, the patient developed 5 clinical exacerbations. Six cerebrospinal fluid (CSF) examinations were performed, 3 during relapses and 3 during remitting phases: all the CSF specimens obtained during relapses showed granulocyte pleocytosis and increased protein level, whereas CSF was normal during stationary phases. Oligoclonal banding was always absent. Spinal cord MRI showed altered signal at cervical and thoracic levels. We did not find any concomitant systemic disease. The case we report underlines the importance of CSF examination during clinical relapse in NMO diagnosis.


Subject(s)
Neuromyelitis Optica/cerebrospinal fluid , Recurrence , Disability Evaluation , Granulocytes/pathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neuromyelitis Optica/diagnosis , Proteins/analysis , Time Factors
14.
Neurology ; 60(4): 634-9, 2003 Feb 25.
Article in English | MEDLINE | ID: mdl-12601105

ABSTRACT

BACKGROUND: MxA is an antiviral protein exclusively induced by type I interferons (IFN) and some viruses, and MxA gene expression is one of the most appropriate markers for measuring the biologic activity of exogenous IFNbeta. METHODS: A new quantitative-competitive PCR method was used to quantify MxA mRNA in peripheral blood mononuclear cells of 99 treatment-naïve and 92 IFNbeta-treated patients with MS (22 Avonex, 17 Betaferon, and 53 Rebif-22). Every 3 months, IFNbeta-induced neutralizing antibodies (NAb) were evaluated in sera using a cytopathic effect assay. Three categories of patients were identified: NAb negative (NAb-), persistent NAb positive (NAb+, >or=2 consecutive positive samples), and isolated NAb+ (one positive sample). RESULTS: Treatment-naïve patients expressed detectable MxA mRNA levels (mean = 36 +/- 32 fg MxA/pg glyceraldehyde-3-phosphate dehydrogenase (GAPDH); range 1 to 160) and an upper normal threshold was established (mean + 3 SD = 132 fg MxA/pg GAPDH). IFNbeta-treated patients exhibited more than 11-fold higher levels (mean = 412 +/- 282 fg MxA/pg GAPDH; range 16 to 1,172). However, 17 patients did not exhibit an increase in MxA mRNA level; 15 of these 17 patients showed a concurrent Nab+ titer. Moreover, 13 were persistent NAb+. Isolated NAb+ patients did not show a decrease in bioavailability of IFNbeta (n = 9; mean = 567 +/- 366 fg MxA/pg GAPDH; range 83 to 1,120). In NAb- patients, bioavailability was comparable among the three different IFNbeta preparations 12 hours after injection. CONCLUSION: During IFNbeta therapy, the presence of NAb reduced or abolished bioavailability in a relevant percentage of patients. These data could be important for the early detection of patients with MS who are not responsive to IFNbeta therapy.


Subject(s)
Antibodies/blood , Interferon-beta/immunology , Multiple Sclerosis/immunology , Biological Availability , GTP-Binding Proteins/genetics , Humans , Interferon beta-1a , Interferon beta-1b , Interferon-beta/pharmacokinetics , Interferon-beta/therapeutic use , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Multiple Sclerosis/blood , Multiple Sclerosis/drug therapy , Myxovirus Resistance Proteins , Polymerase Chain Reaction/methods , RNA, Messenger/metabolism , Reference Values
15.
J Immunol Methods ; 262(1-2): 187-90, 2002 Apr 01.
Article in English | MEDLINE | ID: mdl-11983232

ABSTRACT

Previously, we have reported the development of a new quantitative-competitive polymerase chain reaction (qc-PCR) method to evaluate interferon-beta (IFNbeta) bioavailability in multiple sclerosis (MS) patients, by measuring mRNA of mixovirus resistance protein A (MxA). Here we show that our assay is also able to assess IFNalpha bioavailability in hepatitis C virus (HCV) patients treated with different IFNalpha regimens. Indeed, our method was able to detect a slight constitutive expression of MxA mRNA in untreated HCV patients (median=70 fgMxA/pgGAPDH) and a significant induction 12 h after the first IFNalpha administration (median=750 fgMxA/pgGAPDH).


Subject(s)
Antiviral Agents/pharmacokinetics , GTP-Binding Proteins , Hepatitis C/blood , Hepatitis C/drug therapy , Interferon-alpha/pharmacokinetics , Polymerase Chain Reaction/methods , Proteins/analysis , RNA, Messenger/analysis , Antiviral Agents/therapeutic use , Biological Availability , Humans , Interferon-alpha/therapeutic use , Leukocytes, Mononuclear/metabolism , Myxovirus Resistance Proteins , Proteins/genetics
16.
J Immunol Methods ; 256(1-2): 141-52, 2001 Oct 01.
Article in English | MEDLINE | ID: mdl-11516761

ABSTRACT

Intracellular expression of human myxovirus protein A (MxA) is exclusively induced by type I IFNs (IFNalpha,beta,omega) or by some viruses and it is strongly increased under IFN treatment. We set up an internally controlled quantitative-competitive polymerase chain reaction (qc-PCR) that quantifies MxA mRNA expressed in human peripheral blood mononuclear cells (PBMC). Our qc-PCR is accurate because the mean ratio of copy number estimated by qc-PCR to that quantified spectrophotometrically is 1.08+/-0.03, moreover it is repeatable with high sensitivity (1 fg MxA/pg GAPDH). MxA mRNA was tested in 47 Relapsing-Remitting Multiple Sclerosis (RR-MS) untreated patients and in 48 patients treated with one of the 3 IFNbeta licensed for MS (24 with Rebif, 14 with Avonex and 10 with Betaferon). All the 48 treated patients were negative to IFNbeta neutralising antibodies (NABs) as tested in our laboratory using a cytopathic assay (CPE). MxA mRNA levels were detectable in all untreated patients (mean 24+/-18 fg MxA/pg GAPDH) and significantly higher levels were found in all the treated patients 12 h after IFNbeta administration (mean 499+/-325 fg MxA/pg GAPDH); furthermore, the three types of IFNbeta showed comparable bioavailability. Our data indicate that the bioavailability of the three available types of IFNbeta can be evaluated by MxA qc-PCR.


Subject(s)
GTP-Binding Proteins , Interferon-beta/pharmacology , Multiple Sclerosis/drug therapy , Polymerase Chain Reaction/methods , Proteins/genetics , Humans , Leukocytes, Mononuclear/immunology , Multiple Sclerosis/immunology , Myxovirus Resistance Proteins , Protein Biosynthesis , RNA, Messenger/biosynthesis , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...